文献速递乳房整形与再造显微修复重建

乳腺癌围手术期激素治疗对腹直肌横肌皮瓣腹部并发症的影响

The Impact of Perioperative Hormonal Therapy for Breast Cancer on Transverse Rectus Abdominis Myocutaneous Flap Abdominal Complications.
PubMed 文献 · Ann Plast Surg · 2018-01-01

回顾性分析2003至2015年单中心358例带蒂腹直肌横肌皮瓣乳房重建患者,比较激素治疗与否及具体药物暴露的腹部并发症。激素治疗组与未治疗组疝发生率无显著差异;来曲唑暴露者疝和感染发生率较未治疗组升高。

要点

  • 带蒂TRAM皮瓣重建患者总体疝发生率为5.9%。
  • 激素治疗组疝发生率6.9% vs 未治疗组3.9%,差异无统计学意义(P=0.359)。
  • 来曲唑暴露者疝发生率13.5%(P=0.037)、感染发生率21.6%(P=0.013),均高于未治疗组。

核心结论

  • 激素治疗是乳腺癌化学预防的有用辅助手段,但接受带蒂TRAM皮瓣重建的患者使用来曲唑可能导致某些并发症发生率增加。

研究设计与样本

  • 回顾性队列研究,纳入2003至2015年单中心由资深作者行TRAM皮瓣手术的乳腺癌或高危状态患者358例,查阅病历记录人口学、合并症、治疗及腹部并发症,按激素治疗使用及具体药物暴露分组进行统计分析。

主要发现

  • 总体疝发生率为5.9%(358例中)。
  • 231例(64.5%)接受激素治疗,127例(35.5%)未接受。
  • 激素治疗组疝发生率6.9% vs 未治疗组3.9%,差异无统计学意义(P=0.359)。
  • 他莫昔芬暴露者和阿那曲唑暴露者并发症发生率与未治疗组相比无显著差异。
  • 来曲唑暴露者疝发生率13.5%(P=0.037)、感染发生率21.6%(P=0.013),未治疗组分别为3.9%和7.1%。

临床怎么用

  • 原文结论指出激素治疗是乳腺癌化学预防的有用辅助手段,但带蒂TRAM皮瓣重建患者使用来曲唑可能导致某些并发症发生率增加。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The pedicled transverse rectus abdominis myocutaneous (TRAM) flap is a reliable reconstructive option in breast cancer patients; however, it carries known risk of donor site hernia formation. Some hormonal therapy drugs have been associated with hernia formation in animal models. Minimal data exist concerning impact of hormonal therapy for breast cancer on abdominal donor site complications after breast reconstruction. METHODS: Patients who underwent TRAM flap for breast cancer or high-risk status at a single institution by the senior author from 2003 to 2015 were identified. Charts were reviewed. Patient demographics, comorbidities, treatments, and abdominal complications were recorded. Patients were divided into groups based on use of hormonal therapy as well as exposure to specific drugs. Statistical analyses were performed. RESULTS: A total of 358 patients were included. Overall hernia rate was 5.9%. About 231 (64.5%) patients had hormonal therapy, whereas 127 (35.5%) did not. Difference in hernia formation was not statistically significant between the hormonal therapy group (6.9%) and the no hormonal therapy group (3.9%; P = 0.359). Patients exposed to tamoxifen and those exposed to anastrozole had no significant difference in complication rates compared with the no hormonal therapy group, whereas patients exposed to letrozole had increased rate of hernia (13.5%; P = 0.037) and infection (21.6%; P = 0.013) compared with the no hormonal therapy group (3.9% and 7.1%, respectively). CONCLUSIONS: Hormonal therapy is a useful adjunct for chemoprevention in breast cancer; however, use of letrozole in patients undergoing reconstruction with pedicled TRAM can lead to increase in certain complication rates.

来源:Ann Plast Surg,查看原文。版权归原作者所有。

引用

  1. Huber KM, Clayman E, Kumar A, et al. The Impact of Perioperative Hormonal Therapy for Breast Cancer on Transverse Rectus Abdominis Myocutaneous Flap Abdominal Complications. Ann Plast Surg. 2018. PMID: 29369111. doi:10.1097/SAP.0000000000001323

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。